Why Chinese Fentanyl Factories Are Making Peptides Now
Summary
The Journal investigates how Chinese chemical manufacturers, previously supplying fentanyl precursors to drug cartels, are pivoting to sell unapproved peptides to U.S. consumers. Hosted by Imani Moise with contributor Patricia Kausman, the episode highlights how these firms exploit the booming wellness trend and lax regulatory oversight to profit from a gray market that has surged to over $10 million in monthly crypto purchases. The report details how these companies use mislabeled shipments to bypass customs, noting that selling peptides directly to individuals is often more lucrative and …
Topics discussed
Introduction to Chinese chemical producers and fentanyl
The scale of the U.S. fentanyl crisis and precursor trade
Pivot from fentanyl precursors to peptides
Show intro and sponsor read
Investigating Anri Renchen's website and products
DOJ indictment and lack of enforcement consequences
Chinese export controls driving the market shift
Sponsor read for Anthropic
Social media hype and celebrity endorsement of peptides
Scientific skepticism and FDA approval status
Explosion in crypto peptide sales and profitability
Mislabeled shipments and customs evasion tactics
Regulatory gaps and consumer willingness to buy
Conclusion: The fast-fashion approach to wellness chemicals
Listen ad-free on Castria